Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT-MDS
2022-500430-29-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Luspatercept with Epoetin alfa (2 arms). Planned start Oct 2023; status: authorised.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-500430-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500430-29-00.